keyword
MENU ▼
Read by QxMD icon Read
search

Treatment of chemotherapy caused thrombocytopenia

keyword
https://www.readbyqxmd.com/read/28152765/evaluation-of-relative-thrombocytopenia-identification-of-neuropathy-and-bleeding-risk-secondary-to-utilization-of-neuromodulating-agents-in-multiple-myeloma-patients-receiving-autologous-stem-cell-transplant-treated-with-melphalan-bortezomib-and-lenalidomide
#1
Joel Marcus, Robyn Jackson, Marco A Ruiz, Ryan Patrick Griffin, Rubina Hafeez Khan
212 Background: Chemotherapy-induced polyneuropathy (CIPN) is a crippling manifestation in multiple myeloma (MM) patients that requires attentiveness to safety and quality of life.(2) Bortezomib, lenalidomide, and melphalan are commonly utilized chemotherapy agents that can cause both CIPN(3,4) and significant myelosuppression. Within this subset of patients we wish to insure efficacy and minimization of neuropathic pain while being mindful of bleeding risks. METHODS: IRB approval was obtained for a retrospective study of patients with MM who received a bone marrow transplant (BMT)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28133095/-nab-paclitaxel-plus-gemcitabine-hydrochloride-in-patients-with-metastatic-or-recurrent-pancreatic-cancer-a-single-institution-experience
#2
Yutaka Takeda, Yoshiteru Katsura, Yoshiaki Ohmura, Takuya Sakamoto, Yasuki Akiyama, Ryuichi Kuwahara, Yoshihiro Morimoto, Tomo Ishida, Yasuo Oneda, Kouhei Murakami, Atsushi Naito, Yoshinori Kagawa, Atsushi Takeno, Takeshi Kato, Shigeyuki Tamura
BACKGROUND: Pancreatic adenocarcinoma is one of the leading causes of cancer deaths in Japan.Albumin -bound paclitaxel (nab-paclitaxel)plus gemcitabine hydrochloride(GEM)combination chemotherapy provided significant improvements in the overall and progression-free survival in a phase III trial in Europe and America and a phase II trial in Japan.As a result, this combination therapy was approved for use in Japan. METHODS: We evaluated the efficacy of nab-paclitaxel plus GEM with metastatic or recurrent pancreatic cancer...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28079805/toxicities-of-different-first-line-chemotherapy-regimens-in-the-treatment-of-advanced-ovarian-cancer-a-network-meta-analysis
#3
COMPARATIVE STUDY
Chang-Ping Qu, Gui-Xia Sun, Shao-Qin Yang, Jun Tian, Jin-Ge Si, Yi-Feng Wang
BACKGROUND: Ovarian cancer (OC) is the 5th leading cause of cancer-related deaths around the world, and several chemotherapy regimens have been applied in the treatment of OC. We aim to compare toxicities of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) using network meta-analysis. METHODS: Literature research in Cochrane Library, PubMed, and EMBASE was performed up to November 2015. Eligible randomized controlled trials (RCTs) of different chemotherapy regimens were included...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27884519/production-and-characterization-of-genetically-modified-human-il-11-variants
#4
Emiko Sano, Toshiaki Takei, Takuya Ueda, Kouhei Tsumoto
Interleukin-11 (IL-11) has been expected as a drug on severe thrombocytopenia caused by myelo-suppressive chemotherapy. Whereas, development of IL-11 inhibitor is also expected for a treatment against IL-11 related cancer progression. Here, we will demonstrate the creation of various kinds of genetically modified hIL-11s. Modified vectors were constructed by introducing N- or O-glycosylation site on the region of hIL-11 that does not belong to the core α-helical motif based on the predicted secondary structure...
February 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/27797129/alternative-agents-to-prophylactic-platelet-transfusion-for-preventing-bleeding-in-people-with-thrombocytopenia-due-to-chronic-bone-marrow-failure-a-meta-analysis-and-systematic-review
#5
REVIEW
Michael Desborough, Andreas V Hadjinicolaou, Anna Chaimani, Marialena Trivella, Paresh Vyas, Carolyn Doree, Sally Hopewell, Simon J Stanworth, Lise J Estcourt
BACKGROUND: People with thrombocytopenia due to bone marrow failure are vulnerable to bleeding. Platelet transfusions have limited efficacy in this setting and alternative agents that could replace, or reduce platelet transfusion, and are effective at reducing bleeding are needed. OBJECTIVES: To compare the relative efficacy of different interventions for patients with thrombocytopenia due to chronic bone marrow failure and to derive a hierarchy of potential alternative treatments to platelet transfusions...
October 31, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27725911/comparison-between-nedaplatin-and-cisplatin-plus-docetaxel-combined-with-intensity-modulated-radiotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma-a-multicenter-randomized-phase-ii-clinical-trial
#6
Chunyuan Tang, Fang Wu, Rensheng Wang, Heming Lu, Guisheng Li, Meilian Liu, Haisheng Zhu, Jinxian Zhu, Yong Zhang, Kai Hu
Nasopharyngeal carcinoma (NPC) is highly incident in southern China. Metastasis is the major cause of death in NPC patients. Concurrent chemoradiotherapy (CCRT) has been accepted as standard in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, induction chemotherapy (IC) also has benefits in this disease, especially in the patients with certain high-risk factors such as bulky and/or extensive nodal disease. It has been presented that adding IC to CCRT might be a reasonable approach and need more work to confirm...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27658824/hemophagocytic-lymphohistiocytosis-responding-to-withdrawal-of-gluten-a-case-report
#7
Nicholas J Fordham, Richa Ajitsaria, Leena Karnik, Subarna Chakravorty
BACKGROUND: This is the first documented case of a patient with hemophagocytic lymphohistiocytosis in association with coeliac disease. There was complete clinical and biochemical remission of hemophagocytic lymphohistiocytosis following the introduction of a gluten-free diet. CASE PRESENTATION: A 7-year-old white girl presented with fevers and maculopapular rash with a recent history of tonsillitis. Blood tests revealed thrombocytopenia (64×10(9)/L), anemia (80 g/L), hypofibrinogenemia (1 g/L), and hyperferritinemia (71,378 μg/L)...
2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27230031/successful-treatment-continuation-with-a-single-mild-partial-splenic-embolization-for-thrombocytopenia-caused-by-oxaliplatin-based-chemotherapy-for-advanced-colon-cancer
#8
Joichi Heianna, Osamu Muto, Takaharu Miyauchi, Wataru Endo, Aki Togashi, Kimei Azama, Sadayuki Murayama
We report the case of a patient with advanced colon cancer receiving oxaliplatin-based chemotherapy that was able to continue systemic chemotherapy by performing mild partial splenic embolization (PSE) for thrombocytopenia caused by splenomegaly due to oxaliplatin. Mild PSE may be useful for thrombocytopenia due to splenomegaly in cancer patients because it provides more treatment opportunities.
May 2016: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/27228575/the-effect-of-amifostine-on-differentiation-of-the-human-megakaryoblastic-dami-cell-line
#9
Hai-Tao Wang, Bo Yang, Bo Hu, Xiao-Hua Chi, Long-Long Luo, Hong-Qi Yang, Xiao-Ling Lang, Jing Geng, Chun-Xia Qiao, Yan Li, Xiao-Xiong Wu, Hong-Li Zhu, Ming Lv, Xue-Chun Lu
Amifostine is a cytoprotective drug that was initially used to control and treat nuclear radiation injury and is currently used to provide organ protection in cancer patients receiving chemotherapy. Clinical studies have also found that amifostine has some efficacy in the treatment of cytopenia caused by conditions such as myelodysplastic syndrome and immune thrombocytopenia, both of which involve megakaryocyte maturation defects. We hypothesized that amifostine induced the differentiation of megakaryocytes and investigated this by exposing the human Dami megakaryocyte leukemia cell line to amifostine (1 mmol/L)...
August 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27077849/campylobacter-jejuni-fatal-sepsis-in-a-patient-with-non-hodgkin-s-lymphoma-case-report-and-literature-review-of-a-difficult-diagnosis
#10
REVIEW
Maria Teresa Gallo, Enea Gino Di Domenico, Luigi Toma, Francesco Marchesi, Lorella Pelagalli, Nicola Manghisi, Fiorentina Ascenzioni, Grazia Prignano, Andrea Mengarelli, Fabrizio Ensoli
Campylobacter jejuni (C. jejuni) bacteremia is difficult to diagnose in individuals with hematological disorders undergoing chemotherapy. The cause can be attributed to the rarity of this infection, to the variable clinical presentation, and to the partial overlapping symptoms underlying the disease. Here, we report a case of a fatal sepsis caused by C. jejuni in a 76-year-old Caucasian man with non-Hodgkin's lymphoma. After chemotherapeutic treatment, the patient experienced fever associated with severe neutropenia and thrombocytopenia without hemodynamic instability, abdominal pain, and diarrhea...
April 12, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27057813/conservative-chemotherapy-in-gestational-trophoblastic-disease-experience-with-etoposide-methotrexate-and-dactinomycin-chemotherapy
#11
Seung Won Byun, Tae Chul Park, Seog Nyeon Bae
OBJECTIVE: The goal of this study was to evaluate the efficacy, toxicity, and survival of patients in our institution treated by EMA (etoposide, methotrexate [MTX], and dactinomycin) chemotherapy for 3 groups of patients: ones that had low-risk gestational trophoblastic disease (GTD) that was resistant to MTX (group A), those with high-risk GTD (group B), and the group having low-risk GTD but the cancer being metastatic (group C). METHODS: The medical records of 58 patients who received EMA chemotherapy in groups A, B, and C in the 2000 to 2012 period at St Mary's Hospital were examined...
May 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/26967234/-changes-in-the-prognosis-and-treatment-of-waldenstr%C3%A3-m-macroglobulinemia-literature-overview-and-own-experience
#12
REVIEW
Zdeněk Adam, Luděk Pour, Marta Krejčí, Sabina Ševčíková, Eva Pourová, Eva Ševčíková, Zdeněk Král, Jiří Mayer
Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration. The disease has an indolent course, the treatment is only initiated when the disease has begun to damage its carrier. The following symptoms are regarded as proven indications for initiating therapy: B symptoms, symptomatic lymphadenopathy, splenomegaly, anemia with hemoglobin below 100 g / l or thrombocytopenia < 100 × 10(9)/l, caused by lymphoplasmacytic bone marrow infiltration...
January 2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/26805364/-folfirinox-combination-chemotherapy-in-patients-with-metastatic-or-recurrent-pancreatic-cancer-a-single-institution-experience
#13
Yutaka Takeda, Yoshiteru Katsura, Yoshiaki Ohmura, Yoshihiro Morimoto, Tomo Ishida, Yurina Motoyama, Yasuo Ohneda, Yasufumi Sato, Ryuichi Kuwahara, Kohei Murakami, Atsushi Naito, Yoshinori Kagawa, Masatsugu Okishiro, Atsushi Takeno, Chiyomi Egawa, Takeshi Kato, Shigeyuki Tamura
Pancreatic adenocarcinoma is one of the leading causes of cancer-related deaths in Japan. oxaliplatin: L-OHP, irinotecan: CPT-11, fluorouracil: 5-FU, and Leucovorin: l-LV (FOLFIRINOX) combination chemotherapy provided significant improvements in overall and progression-free survival in a phase Ⅲ trial in France and in a phase Ⅱ trial in Japan. As a result, this combination therapy was approved for use in Japan. We evaluated the efficacy of FOLFIRINOX in metastatic or recurrent pancreatic cancer. Between October 2014 and July 2015, 10 patients received mFOLFIRINOX as follows: 2-hour infusion of LOHP at 85 mg/m2, 2-hour infusion of l-LV at 200 mg/m2 and infusion of CPT-11 over 90 min at 150 mg/m2, followed by continuous infusion of 5-FU over 46 hours at 2,400mg/m2...
November 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26805292/-a-case-of-idiopathic-thrombocytopenic-purpura-during-adjuvant-chemotherapy-for-colon-cancer
#14
Yoshihiro Takahara, Shinichi Ozawa, Takeshi Ogasawara, Takashi Shida, Satoru Nomura, Yoshiharu Sato, Makoto Takahashi
A 76-year-old man underwent surgery for sigmoid colon cancer. The pathological finding was stage Ⅱ with a high-risk of recurrence (SI [bladder], l y0, v2, pN0, H0, P0, M0). He was treated with TS-1 as adjuvant chemotherapy. After the 1 course of chemotherapy, his platelet count was 4,000/mL. The high index of platelet associated IgG (PA-IgG) and bone marrow examination suggested that thrombocytopenia was caused by idiopathic thrombocytopenic purpura. The platelet count improved by prednisolone administration and Helicobacter pylori eradication treatment...
November 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26779428/a-case-of-gemcitabine-induced-thrombotic-microangiopathy-in-a-urothelial-tumor-patient-with-a-single-kidney
#15
Hyunjin Ryu, Eunjeong Kang, Seokwoo Park, Sehoon Park, Kyoungbun Lee, Kwon Wook Joo, Hajeong Lee
Thrombotic microangiopathy (TMA) is a rare complication of gemcitabine treatment. A 55-year-old man with a history of urothelial cancer underwent right ureteronephrectomy and palliative chemotherapy. The patient presented with dyspnea, generalized edema with foamy urine, and new-onset hypertension with acute kidney injury (AKI). Although AKI with oliguria was evident, thrombocytopenia and hemolytic anemia were not overt. To determine the cause of rapidly progressive azotemia, kidney biopsy was performed despite a single kidney and revealed chronic TMA...
December 2015: Kidney Research and Clinical Practice
https://www.readbyqxmd.com/read/26590673/standard-first-line-chemotherapy-with-or-without-nintedanib-for-advanced-ovarian-cancer-ago-ovar-12-a-randomised-double-blind-placebo-controlled-phase-3-trial
#16
RANDOMIZED CONTROLLED TRIAL
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor R Mirza, Giovanni Scambia, Werner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter
BACKGROUND: Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated the combination of nintedanib with standard carboplatin and paclitaxel chemotherapy in patients with newly diagnosed advanced ovarian cancer. METHODS: In this double-blind phase 3 trial, chemotherapy-naive patients (aged 18 years or older) with International Federation of Gynecology and Obstetrics (FIGO) IIB-IV ovarian cancer and upfront debulking surgery were stratified by postoperative resection status, FIGO stage, and planned carboplatin dose...
January 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26576687/comparison-of-different-platelet-count-thresholds-to-guide-administration-of-prophylactic-platelet-transfusion-for-preventing-bleeding-in-people-with-haematological-disorders-after-myelosuppressive-chemotherapy-or-stem-cell-transplantation
#17
REVIEW
Lise J Estcourt, Simon J Stanworth, Carolyn Doree, Sally Hopewell, Marialena Trivella, Michael F Murphy
BACKGROUND: Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding.This is an update of a Cochrane review first published in 2004, and previously updated in 2012 that addressed four separate questions: prophylactic versus therapeutic-only platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments...
November 18, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26505729/different-doses-of-prophylactic-platelet-transfusion-for-preventing-bleeding-in-people-with-haematological-disorders-after-myelosuppressive-chemotherapy-or-stem-cell-transplantation
#18
REVIEW
Lise J Estcourt, Simon Stanworth, Carolyn Doree, Marialena Trivella, Sally Hopewell, Patricia Blanco, Michael F Murphy
BACKGROUND: Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in people who are thrombocytopenic due to bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding.This is an update of a Cochrane review first published in 2004, and updated in 2012 that addressed four separate questions: prophylactic versus therapeutic-only platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments...
October 27, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/26422767/a-therapeutic-only-versus-prophylactic-platelet-transfusion-strategy-for-preventing-bleeding-in-patients-with-haematological-disorders-after-myelosuppressive-chemotherapy-or-stem-cell-transplantation
#19
REVIEW
Gemma L Crighton, Lise J Estcourt, Erica M Wood, Marialena Trivella, Carolyn Doree, Simon Stanworth
BACKGROUND: Platelet transfusions are used in modern clinical practice to prevent and treat bleeding in thrombocytopenic patients with bone marrow failure. Although considerable advances have been made in platelet transfusion therapy in the last 40 years, some areas continue to provoke debate, especially concerning the use of prophylactic platelet transfusions for the prevention of thrombocytopenic bleeding.This is an update of a Cochrane review first published in 2004 and updated in 2012 that addressed four separate questions: therapeutic-only versus prophylactic platelet transfusion policy; prophylactic platelet transfusion threshold; prophylactic platelet transfusion dose; and platelet transfusions compared to alternative treatments...
September 30, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25952492/managing-thrombocytopenia-associated-with-cancer-chemotherapy
#20
REVIEW
David J Kuter
Thrombocytopenia is a common problem in cancer patients. Aside from bleeding risk, thrombocytopenia limits chemotherapy dose and frequency. In evaluating thrombocytopenic cancer patients, it is important to assess for other causes of thrombocytopenia, including immune thrombocytopenia, coagulopathy, infection, drug reaction, post-transfusion purpura, and thrombotic microangiopathy. The incidence of chemotherapy-induced thrombocytopenia varies greatly depending on the treatment used; the highest rates of this condition are associated with gemcitabine- and platinum-based regimens...
April 2015: Oncology (Williston Park, NY)
keyword
keyword
116182
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"